指南与共识肺结节与肺癌间质性肺疾病呼吸危重症与机械通气

胸部CT诊断与临床管理:分子靶向药物及免疫检查点抑制剂相关肺炎——Fleischner学会立场文件

Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
指南 / 共识 · Chest · 2021-01-12

Fleischner学会发布立场文件,针对分子靶向药物和免疫检查点抑制剂(ICI)相关肺炎(DRP)提出诊断标准与管理推荐。DRP诊断需排除其他已知原因,影像学按分布和模式评估,CT模式反映急性、亚急性及慢性间质病变。治疗包括停药、免疫抑制治疗及支持措施。

要点

  • DRP诊断需排除其他潜在已知原因,影像学评估应结合肺实质异常分布。
  • CT模式可反映急性、亚急性及慢性间质病变,单一药物可对应多种影像模式。
  • 治疗包括停药、免疫抑制治疗及支持措施,必要时辅以氧疗和重症监护。

核心结论

  • 本立场文件提供了药物相关肺炎(DRP)的诊断标准和管理推荐,适用于放射科医生、临床医生、临床试验研究者及申办方等。

研究设计与样本

  • Fleischner学会发布的立场文件,基于专家共识提出诊断标准与管理推荐。

主要发现

  • 分子靶向药物和免疫检查点抑制剂(ICI)的使用增加了肺毒性发生频率并拓宽了其谱系,尤其在癌症患者中。
  • DRP症状严重程度可从轻微或无到危及生命并快速进展至死亡。
  • CT模式反映急性(弥漫性肺泡损伤)间质性肺炎和短暂性(单纯性肺嗜酸粒细胞增多)肺部异常、亚急性间质病(机化性肺炎和过敏性肺炎)及慢性间质病(非特异性间质性肺炎)。
  • 单一药物可关联多种影像学模式。

关键数值与推荐

  • DRP诊断通常通过排除其他潜在已知原因而实现。
  • 影像学特征评估应考虑肺实质异常的分布(放射学模式方法)。
  • 治疗通常包括停药、免疫抑制治疗或两者兼有,以及支持措施,最终可能包括 supplementary oxygen 和重症监护。

临床怎么用

  • 对疑似DRP患者,应排除其他已知原因,结合影像学模式(急性、亚急性、慢性)进行评估。
  • 治疗以停药和/或免疫抑制为主,辅以支持措施,必要时氧疗和重症监护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased the frequency and broadened the spectrum of lung toxicity, particularly in patients with cancer. The diagnosis of drug-related pneumonitis (DRP) is usually achieved by excluding other potential known causes. Awareness of the incidence and risk factors for DRP is becoming increasingly important. The severity of symptoms associated with DRP may range from mild or none to life-threatening with rapid progression to death. Imaging features of DRP should be assessed in consideration of the distribution of lung parenchymal abnormalities (radiologic pattern approach). The CT patterns reflect acute (diffuse alveolar damage) interstitial pneumonia and transient (simple pulmonary eosinophilia) lung abnormality, subacute interstitial disease (organizing pneumonia and hypersensitivity pneumonitis), and chronic interstitial disease (nonspecific interstitial pneumonia). A single drug can be associated with multiple radiologic patterns. Treatment of a patient suspected of having DRP generally consists of drug discontinuation, immunosuppressive therapy, or both, along with supportive measures eventually including supplemental oxygen and intensive care. In this position paper, the authors provide diagnostic criteria and management recommendations for DRP that should be of interest to radiologists, clinicians, clinical trialists, and trial sponsors, among others.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest. 2021. PMID: 33450293. doi:10.1016/j.chest.2020.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。